NurExone Biologic Inc. (TSXV:NRX)
Canada · Delayed Price · Currency is CAD | Market Cap | 61.67M +27.4% |
| Revenue (ttm) | n/a |
| Net Income | -9.10M |
| EPS | -0.12 |
| Shares Out | 92.05M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 26,990 |
| Open | 0.6500 |
| Previous Close | 0.6300 |
| Day's Range | 0.6500 - 0.6500 |
| 52-Week Range | 0.5700 - 1.1400 |
| Beta | 0.37 |
| RSI | 58.03 |
| Earnings Date | Apr 13, 2026 |
About NurExone Biologic
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It develops and commercializes the ExoTherapy platform for production of exosome-loaded nanodrugs. The company is also developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of paralysis caused by spinal cord injury using membrane-bound extracellular vesicles technology, as well as to treat traumatic brain injuries and other ne... [Read more]
News
NurExone Biologic's U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization
TORONTO, Ontario and HAIFA, Israel and POMPANO BEACH, Florida, April 07, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) and BioXtek...
NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy
TORONTO and HAIFA, Israel, April 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-bas...
NurExone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement
Exo-Top Inc. positioned as a strategic U.S. subsidiary supporting manufacturing, clinical advancement and long-term value creation Exo-Top Inc. positioned as a strategic U.S. subsidiary supporting man...
NurExone Announces Corporate Updates
Consulting Agreement with Former Bayer Principal Scientist, BOLD Awards Healthcare Finalist Status, and Private Placement Closing Consulting Agreement with Former Bayer Principal Scientist, BOLD Award...
NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update
TORONTO and HAIFA, Israel, Feb. 27, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-...
NurExone Biologic Advances Manufacturing and Regulatory Roadmap with Independent Batch Consistency Results for Exosome Production
Toronto, Ontario and Haifa, Israel--(Newsfile Corp. - February 10, 2026) - NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company devel...
NurExone Appoints Eyal Gabbai to Board, Adding Large-Scale Healthcare System and Capital Markets Expertise
TORONTO and HAIFA, Israel, Jan. 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) today announced changes to its board of director...
NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis
Reducing inflammation helps create a regenerative environment in the Central Nervous System Reducing inflammation helps create a regenerative environment in the Central Nervous System
NurExone Plans Small-Scale of ExoPTEN Clinical Manufacturing in Preparation for FUTURE First in Human USE Pathways
Supported by Scientific Evidence Showing Tissue Repair Quality of Company's Exosomes Supported by Scientific Evidence Showing Tissue Repair Quality of Company's Exosomes
NurExone Biologic Inc. Announces Third Quarter 2025 Financial Results and Provides Corporate Update
TORONTO and HAIFA, Israel, Nov. 28, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pione...
NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises
NurExone Honored at Berlin and Stockholm Conferences for Breakthrough Contributions to Global Life Sciences and Health Innovation NurExone Honored at Berlin and Stockholm Conferences for Breakthrough ...
NurExone Accepted into ARMI's BioFab Startup Lab Strengthening U.S Position in Regenerative Manufacturing
TORONTO and HAIFA, Israel, Nov. 03, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) announced today that it has been accepted to the...
NurExone Invited Presenter at Precision EV Forum in Cambridge, UK
Highlighting Regulatory and Clinical Leadership in Regenerative Exosome Therapies Highlighting Regulatory and Clinical Leadership in Regenerative Exosome Therapies
NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Model
Accelerates Warrant Expirations and POSITIVE Communications Extension Accelerates Warrant Expirations and POSITIVE Communications Extension
NurExone Planning to Establish First U.S. Commercial Manufacturing Facility in Indiana
TORONTO and HAIFA, Israel and INDIANAPOLIS, Sept. 16, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical innovator...
NurExone Biologic Announces Corporate Updates including Israel Patent Grant and Private Placement Closing
TORONTO and HAIFA, Israel, Sept. 11, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a pioneering biopharmaceutical company develop...
NurExone Receives U.S. Patent Allowance for Exosome Manufacturing, Strengthening Supply Chain Readiness
TORONTO and HAIFA, Israel, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a pioneering biopharmaceutical company develop...
NurExone Biologic Inc. Announces Second Quarter 2025 Financial Results
TORONTO and HAIFA, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pione...
NurExone Biologic Announces Preclinical Evidence of Structural Repair in Injured Spinal Cord Tissue following ExoPTEN Treatment
TORONTO and HAIFA, Israel, Aug. 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce new preclinical imaging r...
NurExone's Exosomes Show Stronger Healing Potential Than Industry Standard
Independent Study and Bioanalysis Suggests More Effective Nerve Repair and Faster Wound Healing Independent Study and Bioanalysis Suggests More Effective Nerve Repair and Faster Wound Healing
NurExone Biologic Finalist in Falling Walls Venture 2025 Global Platform Showcasing The World's Most Promising Science-Based Start-Ups
Company to compete for “Science Breakthrough of the Year” at Europe's leading deep-tech summit in Berlin, Germany this November Company to compete for “Science Breakthrough of the Year” at Europe's le...
New ExoPTEN Preclinical Study Indicates Significant Improvement in Walking Quality in Spinal Cord Injury Model
Medium and high doses improved movement quality in up to 100% of the animals in a dose-dependent manner Medium and high doses improved movement quality in up to 100% of the animals in a dose-dependent...
NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update
TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotech company developing exosome-based ther...
NurExone Strengthens Path to Clinical Trials for ExoPTEN with New Manufacturing Process Validation
Company Is also Seeking Shareholder Approval of Amended and Restated Omnibus Plan Company Is also Seeking Shareholder Approval of Amended and Restated Omnibus Plan
NurExone Announces Clinical Trial Plans for Acute Spinal Cord Injury Therapy at Annual Meeting of American Spinal Injury Association
TORONTO and HAIFA, Israel, May 30, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that Professor Nahshon Kno...